Changchun High-tech: Subsidiary Camaijiaolin's clinical trial application approved.

Changchun Gaohin announced on August 11th that its holding subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration. The domestic production drug registration clinical trial application for Jinsai Pharmaceutical's Cabergoline Tablets has been approved. The drug is indicated for hyperprolactinemia.